Einzelansicht Kirchmair

[Back]

Univ.-Prof. Mag. Dr. Johannes Kirchmair

T: +43-1-4277-55104

johannes.kirchmair@univie.ac.at

https://comp3d.univie.ac.at

Summer term 2026

301817 UE MPM 6 - Practical Course: Pharmacoinformatics and structure-based drug design

321029 VO Pharmazeutische Chemie 2 - B15

322026 VU Ausgewählte Kapitel aus der pharmazeutisch-chemischen Forschung - M13

323007 UE Experimental Methods in Drug Discovery und Preclinical Drug Development - MPS6 - (2 Courses)

323101 VU Pharmacoinformatics - MPS5

323102 VU Pharmacoinformatics Practical Course - MPS5

580006 SE Pharma Lectures

580009 SE Journal Club : Molecular Informatics

Winter term 2025

262005 VO Introduction to Computational Biology and Drug Discovery

262006 UE Introduction to Computational Biology and Drug Discovery - Exercises

301817 VO MPM 7 - Lecture course: Model systems in precision medicine - in the context of signature diseases

321004 VO Physik und Informatik für PharmazeutInnen - B3

321028 VO Pharmazeutische Chemie 1 - B15

322001 VO (Bio)pharma. mit Wirkung auf metabol. Störungen & eingeschr. Organ- und Systemfunktionen - M1

322002 VO Antiinfektiva, Antineoplastika und (Bio)pharmazeutika mit Wirkung auf das Immunsystem - M2

322026 VU Ausgewählte Kapitel aus der pharmazeutisch-chemischen Forschung - M13

323005 VO Preclinical Drug Development - MPS4

323009 PR Lab Rotation I - MPS8

323010 PR Lab Rotation II - MPS8

323011 SE Proposal Writing - MPS9 - (2 Courses)

580008 SE SE Journal Club : Molecular Informatics

580009 SE SE Lecture Series Pharma and Food

Summer term 2025

301817 UE MPM 6 - Practical Course: Pharmacoinformatics and structure-based drug design

321029 VO Pharmazeutische Chemie 2 - B15

322026 VU Ausgewählte Kapitel aus der pharmazeutisch-chemischen Forschung - M13

323007 UE Experimental Methods in Drug Discovery und Preclinical Drug Development - MPS6 - (2 Courses)

323101 VU Pharmacoinformatics - MPS5

323102 VU Pharmacoinformatics Practical Course - MPS5

580006 SE Pharma Lectures

580009 SE Journal Club : Molecular Informatics

Thelemann J, Illarionov B, Barylyuk K, Geist J, Kirchmair J, Schneider P et al. Aryl Bis-Sulfonamide Inhibitors of IspF from Arabidopsis thaliana and Plasmodium falciparum. ChemMedChem. 2015;10(12):2090-2098. doi: 10.1002/cmdc.201500382

Braun H, Kirchmair J, Williamson MJ, Makarov VA, Riabova OB, Glen RC et al. Molecular mechanism of a specific capsid binder resistance caused by mutations outside the binding pocket. Antiviral Research. 2015;123:138-145. doi: 10.1016/j.antiviral.2015.09.009

Tyzack JD, Mussa HY, Williamson MJ, Kirchmair J, Glen RC. Cytochrome P450 site of metabolism prediction from 2D topological fingerprints using GPU accelerated probabilistic classifiers. Journal of Cheminformatics. 2014 May 27;6(1):29. doi: 10.1186/1758-2946-6-29

Rechfeld F, Gruber P, Kirchmair J, Boehler M, Hauser N, Hechenberger G et al. Thienoquinolines as novel disruptors of the PKCε/RACK2 protein-protein interaction. Journal of Medicinal Chemistry. 2014 Apr 24;57(8):3235-3246. doi: 10.1021/jm401605c

Mak L, Liggi S, Tan L, Kusonmano K, Rollinger JM, Koutsoukas A et al. Anti-cancer drug development: Computational strategies to identify and target proteins involved in cancer metabolism. Current Pharmaceutical Design. 2013;19(4):532-577. doi: 10.2174/138161213804581855

Kirchmair J, Williamson MJ, Afzal AM, Tyzack JD, Choy APK, Howlett A et al. FAst MEtabolizer (FAME): A Rapid and Accurate Predictor of Sites of Metabolism in Multiple Species by Endogenous Enzymes. Journal of Chemical Information and Modeling. 2013;53(11):2896–2907. doi: 10.1021/ci400503s

Kirchmair J, Howlett A, Peironcely JE, Murrell DS, Williamson MJ, Adams SE et al. How Do Metabolites Differ from Their Parent Molecules and How Are They Excreted? Journal of Chemical Information and Modeling. 2013;53(2):354–367. doi: 10.1021/ci300487z

Xuan S, Wang M, Kang H, Kirchmair J, Tan L, Yan A. Support Vector Machine (SVM) Models for Predicting Inhibitors of the 3 ' Processing Step of HIV-1 Integrase. Molecular Informatics. 2013;32(9-10):811-826. doi: 10.1002/minf.201300107

Kirchmair J, Williamson MJ, Tyzack JD, Tan L, Bond PJ, Bender A et al. Computational Prediction of Metabolism: Sites, Products, SAR, P450 Enzyme Dynamics, and Mechanisms. Journal of Chemical Information and Modeling. 2012;52(3):617–648. doi: 10.1021/ci200542m

Santos-Sierra S, Kirchmair J, Perna A, Reiss D, Kemter K, Roeschinger W et al. DISCOVERY OF NOVEL PHARMACOLOGICAL CHAPERONES FOR PKU THAT CORRECT PHENYLKETONURIA IN VIVO. Journal of Inherited Metabolic Disease. 2012;35(S1):S3.

Distinto S, Esposito F, Kirchmair J, Cardia MC, Gaspari M, Maccioni E et al. Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach. European Journal of Medicinal Chemistry. 2012;50:216-229. doi: 10.1016/j.ejmech.2012.01.056

Santos-Sierra S, Kirchmair J, Perna AM, Reiss D, Kemter K, Roeschinger W et al. Novel pharmacological chaperones that correct phenylketonuria in mice. Human Molecular Genetics. 2012;21(8):1877–1887. doi: 10.1093/hmg/dds001

Distinto S, Yanez M, Alcaro S, Cardia MC, Gaspari M, Sanna ML et al. Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B. European Journal of Medicinal Chemistry. 2012;48:284-295. doi: 10.1016/j.ejmech.2011.12.027

Gleeson MP, Modi S, Bender A, Robinson RLM, Kirchmair J, Promkatkaew M et al. The Challenges Involved in Modeling Toxicity Data In Silico: A Review. Current Pharmaceutical Design. 2012;18(9):1266-1291. doi: 10.2174/138161212799436359

Schuster D, Kowalik D, Kirchmair J, Laggner C, Markt P, Aebischer-Gumy C et al. Identification of chemically diverse, novel inhibitors of 17 beta-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening. The Journal of Steroid Biochemistry and Molecular Biology. 2011 May;125(1-2):148-161. doi: 10.1016/j.jsbmb.2011.01.016

Kirchmair J, Spitzer GM, Liedl KR. Consideration of Water and Solvation Effects in Virtual Screening. In Virtual Screening: Principles, Challenges, and Practical Guidelines. Weinheim: Wiley - V C H. 2011. p. 263-289. (Methods and Principles in Medicinal Chemistry, Vol. 48).

Kirchmair J, Distinto S, Liedl KR, Markt P, Rollinger JM, Schuster D et al. Development of anti-viral agents using molecular modeling and virtual screening techniques. Infectious Disorders, Drug Targets. 2011;11(1):64-93. doi: 10.2174/187152611794407782

Maenz B, Goetz V, Wunderlich K, Eisel J, Kirchmair J, Stech J et al. Disruption of the Viral Polymerase Complex Assembly as a Novel Approach to Attenuate Influenza A Virus. Journal of Biological Chemistry. 2011;286(10):8414-8424. doi: 10.1074/jbc.M110.205534

Koutsoukas A, Simms B, Kirchmair J, Bond PJ, Whitmore AV, Zimmer S et al. From in silico target prediction to multi-target drug design: Current databases, methods and applications. Journal of Proteomics. 2011;74(12):2554-2574. doi: 10.1016/j.jprot.2011.05.011

Rechfeld F, Gruber P, Hofmann J, Kirchmair J. Modulators of Protein-Protein Interactions - Novel Approaches in Targeting Protein Kinases and Other Pharmaceutically Relevant Biomolecules. Current Topics in Medicinal Chemistry. 2011;11(11):1305-1319. doi: 10.2174/156802611795589610